Details

Autor(en) / Beteiligte

• Horimukai, Kenta, MD
• Morita, Kumiko, MD
• Narita, Masami, MD, PhD
• Kondo, Mai, MD
• Kitazawa, Hiroshi, MD, PhD
• Nozaki, Makoto, MD
• Shigematsu, Yukiko, MD
• Yoshida, Kazue, MD, PhD
• Niizeki, Hironori, MD, PhD
• Motomura, Ken-ichiro, MD
• Sago, Haruhiko, MD, PhD
• Takimoto, Tetsuya, MD, PhD
• Inoue, Eisuke, PhD
• Kamemura, Norio, PhD
• Kido, Hiroshi, MD, PhD
• Hisatsune, Junzo, PhD
• Sugai, Motoyuki, DDS, PhD
• Murota, Hiroyuki, MD, PhD
• Katayama, Ichiro, MD, PhD
• Sasaki, Takashi, PhD
• Amagai, Masayuki, MD, PhD
• Morita, Hideaki, MD, PhD
• Matsuda, Akio, PhD
• Matsumoto, Kenji, MD, PhD
• Saito, Hirohisa, MD, PhD
• Ohya, Yukihiro, MD, PhD

Titel

Application of moisturizer to neonates prevents development of atopic dermatitis

Ist Teil von

• Journal of allergy and clinical immunology, 2014-10, Vol.134 (4), p.824-830.e6

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2014

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Background Recent studies have suggested that epidermal barrier dysfunction contributes to the development of atopic dermatitis (AD) and other allergic diseases. Objective We performed a prospective, randomized controlled trial to investigate whether protecting the skin barrier with a moisturizer during the neonatal period prevents development of AD and allergic sensitization. Methods An emulsion-type moisturizer was applied daily during the first 32 weeks of life to 59 of 118 neonates at high risk for AD (based on having a parent or sibling with AD) who were enrolled in this study. The onset of AD (eczematous symptoms lasting >4 weeks) and eczema (lasting >2 weeks) was assessed by a dermatology specialist on the basis of the modified Hanifin and Rajka criteria. The primary outcome was the cumulative incidence of AD plus eczema (AD/eczema) at week 32 of life. A secondary outcome, allergic sensitization, was evaluated based on serum levels of allergen-specific IgE determined by using a high-sensitivity allergen microarray of diamond-like carbon–coated chips. Results Approximately 32% fewer neonates who received the moisturizer had AD/eczema by week 32 than control subjects ( P  = .012, log-rank test). We did not show a statistically significant effect of emollient on allergic sensitization based on the level of IgE antibody against egg white at 0.34 kUA /L CAP-FEIA equivalents. However, the sensitization rate was significantly higher in infants who had AD/eczema than in those who did not (odds ratio, 2.86; 95% CI, 1.22-6.73). Conclusion Daily application of moisturizer during the first 32 weeks of life reduces the risk of AD/eczema in infants. Allergic sensitization during this time period is associated with the presence of eczematous skin but not with moisturizer use.